A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer

Jänne P.A.; Planchard D.; Kobayashi K.; Cheng Y.; Lee C.K.; Valdiviezo N.; Laktionov K.; Yang T.-Y.; Yu Y.; Kato T.; Jiang L.; Chewaskulyong B.; Geater S.L.; Maurel J.-M.; Rojas C.; Takahashi T.; Shepherd F.A.; Tanaka K.; Ghiorghiu D.; Amin N.P.; Armenteros-Monterroso E.; Huang X.; Ahmed Chaudhry A.; Yang J.C.-H. · Future Oncology (2025) · DOI: 10.1080/14796694.2025.2463318